AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
AnaptysBio Price Performance
NASDAQ ANAB opened at $37.50 on Wednesday. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.11 and a beta of -0.29. The company has a 50 day simple moving average of $35.23 and a 200-day simple moving average of $27.63. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. On average, analysts predict that AnaptysBio, Inc. will post -6.84 EPS for the current year.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on ANAB
Hedge Funds Weigh In On AnaptysBio
Hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio during the first quarter valued at $38,000. Headlands Technologies LLC lifted its holdings in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of AnaptysBio by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 2,051 shares in the last quarter. Quest Partners LLC bought a new stake in shares of AnaptysBio in the 4th quarter valued at approximately $119,000. Finally, Virtu Financial LLC bought a new position in AnaptysBio during the first quarter valued at approximately $222,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
See Also
- Five stocks we like better than AnaptysBio
- The Most Important Warren Buffett Stock for Investors: His Own
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is a buyback in stocks? A comprehensive guide for investors
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Stock Splits, Do They Really Impact Investors?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.